Available Technology

Antagonists of the Alpha Epsilon Beta 7 Integrin as Therapeutic Agents for Inflammatory Diseases

The disclosed invention relates to a method of treating and/or preventing the inflammatory response of an autoimmune disease, an allergic disease, a graft-versus-host disease and a transplantation rejection. In particular, this treatment or prevention is accomplished by administering antagonists of the alpha epsilon beta7 integrin. alpha epsilon beta7 is expressed on intra-epithelial lymphocytes (IELs) and on lamina propria (LP) lymphocytes. alpha epsilon beta7 can be upregulated by TGF-beta, and it is speculated to have regulatory functions such as homing or retention. The pathogenesis of chronic intestinal inflammation may depend on the traffic of lymphocytes from sites of induction to sites of inflammation. The inventors have shown that chronic intestinal inflammation can be prevented and reversed in an IL-2 -/- murine model. Administration of anti-alpha epsilon beta7 prevents colonic inflammation and reverses pre-existing inflammation. Therefore, this technology can be used to treat, prevent or reverse inflammatory conditions as well as providing a method of screening for substances effective in reducing the inflammatory effects of alpha epsilon beta7. Bjorn Ludviksson
Abstract: 
The disclosed invention relates to a method of treating and/or preventing the inflammatory response of an autoimmune disease, an allergic disease, a graft-versus-host disease and a transplantation rejection. In particular, this treatment or prevention is accomplished by administering antagonists of the alpha epsilon beta7 integrin. alpha epsilon beta7 is expressed on intra-epithelial lymphocytes (IELs) and on lamina propria (LP) lymphocytes. alpha epsilon beta7 can be upregulated by TGF-beta, and it is speculated to have regulatory functions such as homing or retention. The pathogenesis of chronic intestinal inflammation may depend on the traffic of lymphocytes from sites of induction to sites of inflammation. The inventors have shown that chronic intestinal inflammation can be prevented and reversed in an IL-2 -/- murine model. Administration of anti-alpha epsilon beta7 prevents colonic inflammation and reverses pre-existing inflammation. Therefore, this technology can be used to treat, prevent or reverse inflammatory conditions as well as providing a method of screening for substances effective in reducing the inflammatory effects of alpha epsilon beta7. Bjorn Ludviksson(NIAID)➽ more inventions... Warren Strober (NIAID)➽ more inventions... Rolf Ehrhardt (NIAID)➽ more inventions... PCT Application No. PCT/US99/27817 US Application No. 60/109,957 US Application No. 09/856,544 Admin. Licensing Specialist (ALS), Email: Phone: E-282-1998/0 Updated:Jun 1, 1999
Inventors: 
Rolf Ehrhardt
Patent Number: 
PCT/US99/27817
Internal Laboratory Ref #: 
E-282-1998/0
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin